News und Analysen

While government programs help retirees replace some of their income once they stop working, these initiatives aren't meant to fund all of people's expenses in their golden years. That's why many

Growth stocks are back in style after getting battered in last year's downturn. Some, though, never went out of fashion in the first place. That's the case with this trio of biotech stocks: Vertex

"I don't get no respect." That was the line the late comedian Rodney Dangerfield made famous. But it could also apply to some stocks.

Three Motley Fool contributors identified surprisingly

There's a lot going on with biotech giant Regeneron (NASDAQ: REGN) that may be of interest to investors. The company could soon face biosimilar competition from one of its key growth drivers, Eylea

Companies that can withstand market volatility make for good long-term investments. Ireland-based Medtronic (NYSE: MDT), a major player in the medical device industry, has repeatedly demonstrated

Analysts' price targets can help investors get an idea of whether there's a lot of bullishness surrounding a stock. But in some cases, a high upside can simply be due to elevated price targets that

If you're looking for a high-yield dividend stock in the healthcare sector, you might be interested in comparing Takeda Pharmaceutical (NYSE: TAK) and Viatris (NASDAQ: VTRS).

Both companies offer

Shares of Medtronic (NYSE: MDT) fell 3.1% on Thursday, according to data provided by S&P Global Market Intelligence, giving back yesterday's post-earnings gains after it announced advisors to the

Retirement is a big problem for many Americans. According to a recent poll from BlackRock, just 56% of people believe that they will be able to retire comfortably and have the life they want in

More than three years after deeming COVID-19 a global health emergency, the World Health Organization ended the pandemic's special status in May.

This was certainly welcome news for numerous

Tuesday was a fine day to be a Medtronic (NYSE: MDT) investor. The company's performance in its inaugural quarter of fiscal 2024 was better than expected, and the market rewarded Medtronic shares

Image source: The Motley Fool.

Medtronic (NYSE: MDT)Q1 2024 Earnings CallAug 22, 2023, 8:00 a.m. ET

Ryan Weispfenning

Continue reading

Source Fool.com

Wall Street analysts are upbeat on California-based biotech Illumina (NASDAQ: ILMN) these days, estimating on average that the stock could climb by up to 27% over the next year. But without some

Buying individual stocks can be a smart way to build wealth over time. However, the reality of the situation is that it's exceptionally difficult to consistently beat the market averages over time

Regeneron Pharmaceuticals (NASDAQ: REGN) is a leader in the field of therapeutic proteins, with a history of more than 30 years of innovation and excellence. The biotech has partnered with Bayer to

A new bull market is here ... almost. Some maintain that the S&P 500 has already begun a new bull market. Others, though, argue that the index must reach an all-time high first. Either way, many

Over the past few years, several hot investing trends swept through Wall Street. First, it was the metaverse, and now it's artificial intelligence; there will likely be some new big thing in a year

Viatris (NASDAQ: VTRS) hasn't made for a particularly great investment since it formed nearly three years ago, through a merger of Mylan and Pfizer's Upjohn business. Down 29% since then, it has

Over the past few years, medical device companies have struggled as the pandemic disrupted much of the industry, and economic problems contributed to lower sales and increasing expenses. Healthcare

UnitedHealth Group (NYSE: UNH) has been a top healthcare stock to own for years. Today, it's among the largest healthcare companies in the world, worth $475 billion. Although it's a health insurer

Being a buy-and-hold investor has advantages. For instance, it can be less stressful than day trading, and the combination of time and compounding is a powerful wealth generator. However, with

Pharma giant AbbVie (NYSE: ABBV) performed poorly in the first part of the year, especially after it reported its first-quarter results. This was its first quarterly update following the loss of

Illumina's (NASDAQ: ILMN) stock is down by 15% this year so far, and it's no surprise why. With the new disclosure of a Securities and Exchange Commission (SEC) investigation into its bedraggled

Viatris (NASDAQ: VTRS) could be on the verge of eating the lunch of Novo Nordisk's (NYSE: NVO) two golden cash cows: The diabetes drug Ozempic, and another version that's formulated for weight loss

Healthcare company Amgen (NASDAQ: AMGN) has been a reliable investment to own over what has been a turbulent year for the broader market. Its stock price is up 6.6% in that time, outpacing the 3.2%